NASDAQ:NVAX Novavax - NVAX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.23 -0.78 (-6.49%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.18▼$12.2850-Day Range$8.86▼$17.6152-Week Range$8.75▼$101.39Volume6.47 million shsAverage Volume6.84 million shsMarket Capitalization$881.56 millionP/E RatioN/ADividend YieldN/APrice Target$104.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Novavax MarketRank™ ForecastAnalyst RatingHold2.29 Rating ScoreUpside/Downside723.7% Upside$92.50 Price TargetShort InterestBearish39.38% of Shares Sold ShortDividend StrengthN/ASustainability-0.27Upright™ Environmental ScoreNews Sentiment-0.03Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.49) to ($4.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector667th out of 1,028 stocksBiological Products, Except Diagnostic Industry106th out of 168 stocks 3.1 Analyst's Opinion Consensus RatingNovavax has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 4 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.50, Novavax has a forecasted upside of 723.7% from its current price of $11.23.Amount of Analyst CoverageNovavax has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted39.38% of the outstanding shares of Novavax have been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Novavax has recently increased by 1.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovavax has received a 76.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases ", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Novavax is -0.27. Previous Next 1.6 News and Social Media Coverage News SentimentNovavax has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Novavax this week, compared to 12 articles on an average week.Search InterestOnly 65 people have searched for NVAX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows38 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 46% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Novavax is held by insiders.Percentage Held by Institutions45.70% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Novavax are expected to grow in the coming year, from ($7.49) to ($4.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Novavax (NASDAQ:NVAX) StockNovavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.Read More Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Email Address NVAX Stock News HeadlinesFebruary 4, 2023 | marketbeat.comMarketBeat Week in Review – 1/30 - 2/3 (NVAX)The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shotFebruary 1, 2023 | marketbeat.comNovavax Shares Jumped in January While Others Slipped (NVAX)Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 11, 2023 | marketbeat.com2 Biotechs Making Waves With A Single Product in their Pipeline (NVAX)Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.February 4, 2023 | americanbankingnews.comNovavax (NASDAQ:NVAX) Trading Up 10.6%February 1, 2023 | finance.yahoo.comNovavax Plans To Update Its Covid Shot — But Is NVAX Stock A Buy Today?February 1, 2023 | americanbankingnews.comNovavax (NASDAQ:NVAX) Stock Price Down 6%January 30, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and NovavaxFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 30, 2023 | americanbankingnews.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesJanuary 28, 2023 | seekingalpha.comNovavax: The Vaccine Battle Continues With GaviJanuary 27, 2023 | finance.yahoo.comGaithersburg's Novavax ‘prepared to deliver’ updated Covid-19 vaccine following FDA advisory panel voteJanuary 27, 2023 | finance.yahoo.com3 Great Growth Stocks Down 20% or More to Buy NowJanuary 27, 2023 | finance.yahoo.comNovavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna SlipJanuary 26, 2023 | finance.yahoo.comNew Novavax CEO John Jacobs Takes The Helm — But Is NVAX Stock A Buy Today?January 24, 2023 | finance.yahoo.com3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023January 24, 2023 | finance.yahoo.comJob Cuts Today, What Tomorrow? Big Tech Faces Some Big Tests.January 20, 2023 | finance.yahoo.comCould Novavax Stock Help You Become a Millionaire?January 18, 2023 | finance.yahoo.comAnalysts spell out what new Novavax CEO John Jacobs could mean for the Gaithersburg biotech, its Covid vaccineJanuary 13, 2023 | finance.yahoo.comOutgoing Novavax CEO: 'The government has to get out of the way'January 13, 2023 | finance.yahoo.comNovavax Snags New CEO From Harmony — But Is Novavax Stock A Buy Or A Sell?January 13, 2023 | finance.yahoo.comIf You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have TodayJanuary 13, 2023 | finance.yahoo.comHow Novavax Could Shake Up the Market for Covid-19 VaccinesJanuary 12, 2023 | finance.yahoo.comDon't Blame the Bear Market for This Growth Stock's Jaw-Dropping Sell-OffJanuary 12, 2023 | finance.yahoo.comWith This Big Transition Ahead, Is Novavax a Buy?January 10, 2023 | finance.yahoo.comNovavax CEO reflects on COVID-19, company milestones, and his retirementJanuary 10, 2023 | finance.yahoo.comNovavax (NVAX) Names John Jacobs as New CEO, Shares RiseSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Email Address NVAX Company Calendar Last Earnings11/08/2022Today2/05/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX CUSIP67000210 CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees1,541Year Founded1987Price Target and Rating Average Stock Price Forecast$92.50 High Stock Price Forecast$198.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+831.7%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($17.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,743,750,000.00 Net Margins-71.59% Pretax Margin-70.33% Return on EquityN/A Return on Assets-51.33% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.01 Sales & Book Value Annual Sales$1.15 billion Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value($4.65) per share Price / Book-2.42Miscellaneous Outstanding Shares78,500,000Free Float76,855,000Market Cap$881.56 million OptionableOptionable Beta1.73 Social Links Key ExecutivesJohn C.s JacobsPresident, Chief Executive Officer & DirectorRichard CrowleyChief Operating Officer & Executive Vice PresidentJames Patrick KellyChief Financial Officer, Treasurer & Executive VPGale E. SmithChief Scientist & Senior Vice President-DiscoveryGregory M. GlennPresident-Research & DevelopmentKey CompetitorsAgenusNASDAQ:AGENSangamo TherapeuticsNASDAQ:SGMOBioCryst PharmaceuticalsNASDAQ:BCRXSana BiotechnologyNASDAQ:SANAAnavex Life SciencesNASDAQ:AVXLView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 445,200 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCBought 92,364 shares on 2/2/2023Ownership: 0.158%Wolverine Asset Management LLCBought 285,300 shares on 2/1/2023Ownership: 0.000%DekaBank Deutsche GirozentraleSold 1,950 shares on 2/1/2023Ownership: 0.030%Zurcher Kantonalbank Zurich Cantonalbank Sold 1,570 shares on 2/1/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions NVAX Stock - Frequently Asked Questions Should I buy or sell Novavax stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares. View NVAX analyst ratings or view top-rated stocks. What is Novavax's stock price forecast for 2023? 7 equities research analysts have issued 1 year price objectives for Novavax's shares. Their NVAX share price forecasts range from $27.00 to $198.00. On average, they predict the company's share price to reach $92.50 in the next twelve months. This suggests a possible upside of 723.7% from the stock's current price. View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts. How have NVAX shares performed in 2023? Novavax's stock was trading at $10.28 on January 1st, 2023. Since then, NVAX stock has increased by 9.2% and is now trading at $11.23. View the best growth stocks for 2023 here. When is Novavax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our NVAX earnings forecast. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($2.15) earnings per share for the quarter, missing the consensus estimate of $2.21 by $4.36. The biopharmaceutical company had revenue of $734.58 million for the quarter, compared to analyst estimates of $555.50 million. The company's quarterly revenue was up 310.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.31) EPS. When did Novavax's stock split? Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What guidance has Novavax issued on next quarter's earnings? Novavax issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.00 billion, compared to the consensus revenue estimate of $2.04 billion. What is Stanley C. Erck's approval rating as Novavax's CEO? 46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE). What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." Who are Novavax's major shareholders? Novavax's stock is owned by a number of institutional and retail investors. Top institutional investors include Shah Capital Management (0.91%), Simplex Trading LLC (0.00%), Wolverine Asset Management LLC (0.00%), SG Americas Securities LLC (0.16%), Mendel Capital Management LLC (0.03%) and DekaBank Deutsche Girozentrale (0.03%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View institutional ownership trends. How do I buy shares of Novavax? Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $11.23. How much money does Novavax make? Novavax (NASDAQ:NVAX) has a market capitalization of $881.60 million and generates $2.39 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis. How many employees does Novavax have? The company employs 1,541 workers across the globe. How can I contact Novavax? Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100. This page (NASDAQ:NVAX) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.